No abstract

Artículos de investigación científica Prueba piloto para la elaboración perfil epidemiológico de discapacidad en el municipio de Madrid (Cundinamarca) Pilot test for the development of the health profile of disability in the Madrid Municipality (Cundinamarca) Prova piloto para a elaboração do perfil epidemiológico de deficiência no município de Madrid (Cundinamarca)

No abstract

s e237Results: After 24 weeks of therapy, mean reduction of HBV-DNA level, the percentage of patients with HBV-DNA lower than 5 log10 copies/ml and the percentage of patients with HBV-DNA level decrease of more than 2 log10 copies/ml in group B were significantly higher than those in group A (P < 0.05, respectively). At the end of 24, 48 and 96 weeks, the patients in group B had higher rates of undetectable serum HBV-DNA levels and ALT normalization than those in group A (46% vs 25%, 74% vs 54.2%, 88% vs 70.8%; 52% vs 31.3%, 66% vs 43.8%, 82% vs 62.5%; P < 0.05, respectively). HBeAg seroconversion rate was significant hihger in group B than those in group A (48% vs 27.1%, P < 0.05). There was no evidence of adverse effect in patients treated for up to 96 weeks.Conclusion: Adefovir dipivoxil is an effective treatment option for nucleoside-naive patients with HBeAg-positive chronic hepatitis B, especially for those with high serum ALT levels at baseline. Adefovir dipivoxil treatment through 96 weeks was well tolerated and resulted in continued benefit for patients with HBeAg-positive chronic hepatitis B.